BMO ARK Genomic Revolution ETF SeriesTSX:ARKG
No Matches were found for
- LAST PRICE10.11
- TODAY'S CHANGE (%)0.08 (0.80%)
- Bid / Lots10.09/ 40
- Ask / Lots10.21/ 20
- Open / Previous Close10.11 / 10.03
- Day Range
- 52 Week Range
- Volume4,259
- Overall Morningstar RatingNot Ratedout of funds
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Select an index
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ARKG |
|---|---|---|
| 11:26 ET | 400 | 10.11 |
| 11:33 ET | 500 | 10.09 |
| 11:56 ET | 200 | 10.14 |
| 12:45 ET | 100 | 10.13 |
| 03:36 ET | 3000 | 10.11 |
Asset Class
| US Equity | 89.7% |
|---|---|
| Int'l Equity | 8.3% |
| Cash | 1.3% |
| CDN Equity | 0.8% |
| Fixed Income | 0 |
| Other | 0 |
Sectors
| Healthcare | 96.9% |
|---|---|
| Technology | 1.9% |
| Basic Mat. | 0 |
| Communication Services | 0 |
| Consumer Cyclical | 0 |
| Consumer Defensive | 0 |
| Energy | 0 |
| Financial Serv.s | 0 |
| Industrials | 0 |
| Real Estate | 0 |
| Utilities | 0 |
Geographic Region
| United States | 90.8% |
|---|---|
| Canada | 0.8% |
| Latin America | 0 |
| Africa | 0 |
| Europe | 0 |
| Asia/Oceania | 0 |
| Company Name sortable | Position sortable | Allocation sortable | Allocation sortable1 Month Change | Market Value sortable |
|---|---|---|---|---|
CRISPR Therapeutics AG | Long | 7.2% | -26.99% | $420.2K |
Twist Bioscience Corp | Long | 5.9% | -28.06% | $342.1K |
Exact Sciences Corp | Long | 5.4% | -41.79% | $312.3K |
Recursion Pharmaceuticals Inc Class A | Long | 5.3% | -27.70% | $309.5K |
Beam Therapeutics Inc | Long | 4.3% | -30.80% | $250.5K |
Schrodinger Inc Ordinary Shares | Long | 4.1% | -30.45% | $241.3K |
Intellia Therapeutics Inc | Long | 3.9% | -27.35% | $229.7K |
CareDx Inc | Long | 3.8% | -34.89% | $219.4K |
Ginkgo Bioworks Holdings Inc | Long | 3.7% | -28.26% | $217.5K |
Ionis Pharmaceuticals Inc | Long | 3.7% | -35.01% | $215.1K |
Reports
No reports available
Morningstar Ratings
| Time Horizon | Star Rating |
|---|---|
| Overall Rating | Not Rated |
| 3 Year Rating | Not Rated |
| 5 Year Rating | Not Rated |
| 10 Year Rating | Not Rated |
Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.
Style Box is calculated only using the long position holdings of the portfolio.
Best Fit Index | --- |
|---|---|
Category | Sector Equity |
Sponsor | ARK Investment Management LLC |
Inception | November 17, 2022 |
This fund’s objective is to provide long-term capital growth by investing primarily in equity securities of companies involved in disruptive genomic innovation from around the world.
| Total Net Assets | $5.0M |
|---|---|
| Shares Out. | 400.0K |
| Net Asset Value (NAV) | $10.12 |
| Prem/Discount to NAV | -0.13% |
| P/E Ratio | --- |
| Dividend Yield | 0.99% |
| Dividend per Share | 0.10 CAD |
| Ex-Dividend Date | 12/27/2023 |
| Dividend Payment Date | 01/3/2024 |
| Beta | --- |
| Morningstar Investment Style | Sector Equity |
| Equity Style | Small Cap Growth |
| Credit Quality / Duration | --- |
| Actual Management Fee | 0.75% |
|---|---|
| Actual Mgmt. Expense Ratio (MER) | 0.84% |